Swiss Chemicals Stock News

Why this new SMA launch matters for Partners Group Holding (SWX:PGHN) BlackRock and Partners Group Holding (SWX:PGHN) have introduced a multi alternatives separately managed account solution that packages private equity, private credit, and real assets access for financial advisors in a single, streamlined offering. See our latest analysis for Partners Group Holding. The new SMA launch comes after a weaker recent stretch for the shares, with a 7 day share price return showing a 6.49% decline...

If you have been wondering whether Roche Holding's current share price really lines up with its underlying worth, this article walks you through the key numbers that matter. Over the short term the stock has been relatively steady, with a 0.2% decline over the last 7 days. The 30 day, year to date and 1 year returns sit at 3.8%, 8.7% and 25.8% respectively, and the 3 year and 5 year figures are 41.4% and 33.3%. Recent coverage of Roche has focused on its position as a global healthcare group...

Executive reshuffle puts leadership focus back on core functions Flughafen Zürich (SWX:FHZN) has kicked off a broad management reshuffle, cutting its Executive Board from seven to six members and confirming the planned exit of Chief People & Communication Officer Manuela Staub in July 2026. See our latest analysis for Flughafen Zürich. At a share price of CHF249.6, Flughafen Zürich has seen a 4.44% 7 day share price return but a 4.22% 30 day share price decline. Its 1 year total shareholder...

The Swatch Group AG recently reported full-year 2025 results, with sales of CHF 6,280 million and net income of CHF 3 million, and affirmed an annual dividend of CHF 4.50 per share payable on May 19, 2026. The decision to maintain the dividend despite much weaker profitability offers a clear signal about management’s confidence in the group’s financial resilience and priorities for rewarding shareholders. We will now examine how the earnings weakness paired with the affirmed dividend shapes...

Why Givaudan’s latest earnings and dividend matter for shareholders Givaudan (SWX:GIVN) has put fresh numbers on the table, pairing its full year 2025 earnings release with an annual dividend announcement that gives investors clearer insight into both cash returns and recent business performance. See our latest analysis for Givaudan. The latest earnings and dividend announcement comes after a mixed share price stretch, with a 7 day share price return of 3.58% but a 1 year total shareholder...

Vontobel Holding (SWX:VONN) closed FY 2025 with second half revenue of CHF 741.7 million and basic EPS of CHF 2.94, while trailing 12 month revenue came in at CHF 1.43 billion with basic EPS of CHF 4.99, setting a clear benchmark for the latest reporting stretch. The company has seen revenue move from CHF 694.3 million and basic EPS of CHF 2.44 in 2024’s second half to CHF 741.7 million and CHF 2.94 respectively in 2025’s second half, with trailing net income of CHF 280.1 million framing a...

Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...

Why Vontobel’s latest earnings and dividend matter Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting higher full year 2025 net income and earnings per share, together with asset under management growth and an affirmed annual dividend of CHF 3.00 per share. See our latest analysis for Vontobel Holding. The earnings and dividend announcement has coincided with a clear upswing in sentiment, with a 3.83% 1 day share price return and a 16.12% 90 day share price return...

Revenue growth event puts Compagnie Financière Tradition (SWX:CFT) in focus Compagnie Financière Tradition (SWX:CFT) caught investor attention after reporting 2025 consolidated revenue growth of 11.4% at constant exchange rates, with the fourth quarter advancing 11.7% on higher transaction volumes across asset classes and regions. See our latest analysis for Compagnie Financière Tradition. At a share price of CHF289.0, Compagnie Financière Tradition has had a mixed shorter term run, with a 1...

Most readers would already know that Burkhalter Holding's (VTX:BRKN) stock increased by 8.1% over the past three...

It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...

Barry Callebaut (SWX:BARN) is back in focus after reporting a 22% drop in cocoa division sales volume for the quarter ending November 30, citing weak market demand and a tilt toward higher return cocoa segments. See our latest analysis for Barry Callebaut. The latest cocoa volume setback comes after a period of strong momentum in the share price, with a 12.69% 1 month share price return and an 18.16% 3 month share price return contributing to a 45.54% 1 year total shareholder return, even...

Most readers would already be aware that Swiss Prime Site's (VTX:SPSN) stock increased significantly by 15% over the...

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...

As the eurozone economy continues its modest recovery, with improved consumer and business confidence, European markets have shown resilience amidst global trade and geopolitical concerns. In this environment, dividend stocks can offer stability and income potential, making them an attractive option for investors looking to navigate the current market dynamics.

Sensirion Holding AG has launched the SCD53, a highly intrinsically stable CO₂ sensor designed to maintain long-term accuracy without manual recalibration or exposure to outdoor air, while offering integrated humidity, temperature and optional pressure compensation in a compact, easily integrated package. By eliminating reliance on automatic baseline calibration and enhancing robustness against dust, vibrations and mechanical stress, the SCD53 directly targets challenging applications such...

As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that are trading below their estimated worth can offer potential opportunities for investors seeking value in an environment where confidence is strengthening and economic recovery continues at a steady pace.

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Why ARYZTA’s latest guidance is back in focus ARYZTA (SWX:ARYN) drew fresh attention after its 2025 sales and trading statement call on 22 January, alongside new earnings guidance for 2026 that points to revenue growth and improved performance for the year. For you as an investor, that combination of an updated outlook and a recent company communication creates a new reference point for reassessing ARYZTA’s current valuation, recent share price moves and the risks around its 2026 targets. See...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...

In January 2026, BlackRock and Partners Group launched a first-of-its-kind multi-alternatives separately managed account on the Morgan Stanley wealth platform, giving advisors streamlined access to diversified private equity, private credit, and real assets through three outcome-aligned strategies. This structure is designed to remove common barriers to private market access by consolidating seven evergreen private market funds into a single, operationally simple solution for financial...

Cosmo Pharmaceuticals N.V. recently completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding shares, with Capital Group’s SMALLCAP World Fund, using only existing treasury stock and therefore avoiding dilution for current shareholders. The deal brings a globally recognized institutional investor into Cosmo’s shareholder base while providing additional financial flexibility to support its MedTech AI, dermatology, gastroenterology, and CDMO...

Sika recently expanded its global manufacturing network by opening five new plants in the United States, Argentina, Colombia, Bangladesh, and Tanzania to increase production capacity and reinforce its supply chain in key regions. This expansion underscores Sika’s emphasis on being closer to customers in growth markets, enhancing supply reliability and responsiveness across diverse construction material needs. We’ll now examine how this push to boost production capacity in key growth markets...

Adecco Group (SWX:ADEN) is back in focus after launching a global HR and talent consulting platform under its LHH brand. The move puts more weight on advisory services ahead of the upcoming earnings release. See our latest analysis for Adecco Group. The LHH launch comes as Adecco’s CHF23.20 share price sits slightly lower year to date, with a 4.3% 90 day share price return and an 11.5% 1 year total shareholder return, suggesting recent momentum has picked up after a weaker multi year...